Is AREDS 2 Safe? A Look at Its Side Effects and Benefits

AREDS 2 supplements are considered safe for the large majority of people who take them, but they are not free of side effects, and certain groups need to be more cautious than others. The formulation was specifically redesigned to be safer than its predecessor by swapping out beta-carotene, an ingredient linked to lung cancer in smokers, for lutein and zeaxanthin. That single change addressed the most serious safety concern of the original formula. The remaining risks involve zinc-related urinary problems, a possible link between vitamin E and prostate cancer, and drug interactions that can catch people off guard.

What AREDS 2 Contains and Why It Changed

The original AREDS formula, tested in a landmark trial that began in the 1990s, included high-dose vitamin C (500 mg), vitamin E (400 IU), beta-carotene (15 mg), zinc (80 mg as zinc oxide), and copper (2 mg, added to offset zinc-induced copper loss). The study showed this combination slowed the progression of intermediate age-related macular degeneration to advanced AMD by roughly 25 percent over five years. But the beta-carotene component was a problem. Evidence had been mounting since the mid-1990s that beta-carotene supplements raised lung cancer risk in smokers, and the AREDS trial itself reported a higher rate of lung cancer in participants taking it.

AREDS 2 was designed to test whether lutein (10 mg) and zeaxanthin (2 mg) could replace beta-carotene while preserving or improving the formula’s protective effect, and whether adding omega-3 fatty acids (DHA and EPA) offered any additional benefit. The zinc dose was also tested at a lower level (25 mg versus the original 80 mg). In the five-year primary analysis, the addition of lutein and zeaxanthin did not reach statistical significance for reducing progression to advanced AMD compared with the original formula’s placebo group, while omega-3 fatty acids showed no benefit at all.¹ The real payoff showed up in longer follow-up and in comparisons against beta-carotene specifically, which we will get to below.

How Well AREDS 2 Actually Works

The clearest picture of AREDS 2’s benefit comes from the ten-year follow-up data. When researchers compared everyone who received lutein and zeaxanthin against everyone who did not, the risk of progressing to late AMD was about 9 percent lower in the lutein/zeaxanthin group. That difference was statistically significant. Among participants who had been assigned to beta-carotene in a secondary randomization, swapping to lutein and zeaxanthin cut the risk of progression by roughly 20 percent. And in a head-to-head comparison of participants randomly assigned to lutein/zeaxanthin alone versus beta-carotene alone, lutein/zeaxanthin came out ahead with about a 15 percent lower risk of progression.²

These are modest but meaningful effects. AREDS 2 does not cure AMD or reverse vision loss. It slows progression in people who already have intermediate AMD or advanced AMD in one eye. For someone without AMD or with only very early signs, there is no established benefit to taking the supplement. The people who stand to gain the most are those whose eye doctor has told them they have category 3 or category 4 disease.

Lab research helps explain why these nutrients might protect the retina. Lutein and zeaxanthin are selectively concentrated in the macula, the part of the retina responsible for sharp central vision. In cell studies, lutein reduces the damage that reactive oxygen species inflict on retinal pigment epithelium cells, essentially acting as a shield against oxidative stress.³ Animal studies have similarly shown that antioxidant vitamins reduce markers of oxidative damage and structural changes in the retina.⁴ These findings are consistent with the idea that cumulative oxidative damage contributes to AMD progression, and that flooding the macula with protective pigments can slow that damage down.

The Beta-Carotene and Lung Cancer Risk

The single biggest safety improvement in AREDS 2 was dropping beta-carotene. A meta-analysis combining data from multiple trials found that current smokers taking beta-carotene supplements had roughly a 24 percent higher risk of lung cancer compared with those not taking it.⁵ Among former smokers, the increase was smaller and not statistically significant, but the signal was alarming enough to make beta-carotene unacceptable in a supplement that older adults might take for years or decades.

The AREDS 2 ten-year data confirmed the wisdom of the switch. At that time point, those who had been randomly assigned to beta-carotene had nearly double the odds of developing lung cancer compared with those assigned to lutein and zeaxanthin.² This elevated risk was not limited to active smokers. If you still see an eye vitamin on the shelf that contains beta-carotene, that product is using the outdated original AREDS formula. The current medical consensus is that lutein and zeaxanthin should replace beta-carotene in all AREDS-type supplements, and most major brands have made the change.

Zinc-Related Side Effects

The AREDS 2 formula includes 80 mg of zinc oxide per day (some formulations use 25 mg, as that lower dose was also tested and appeared comparably effective). Either dose is well above the recommended daily allowance of 8 to 11 mg for adults, and high-dose zinc has a real track record of causing problems.

In data drawn from the original AREDS trial, participants taking zinc-containing formulations had a significantly higher rate of hospitalization for genitourinary causes compared with those on non-zinc formulations. The numbers were 11.1 percent versus 7.6 percent. The risk was highest in men, who faced increased hospitalizations related to prostate enlargement and urinary retention. Women on zinc had a notably higher rate of urinary tract infections. Kidney stones in men also trended upward, though that finding did not quite reach statistical significance.⁶

Beyond urinary problems, long-term high-dose zinc interferes with copper absorption. The AREDS formula includes 2 mg of copper specifically to counteract this, but the balance is not always perfect. Copper deficiency from zinc supplementation can cause anemia, numbness and tingling in the extremities, and difficulty walking. A case report described a 76-year-old woman who developed severe pancytopenia and dangerously low copper levels after taking zinc supplements, requiring hospitalization.⁷ That particular case involved zinc supplementation outside of AREDS, but the mechanism is the same: zinc and copper compete for absorption in the gut, and when zinc wins by a large enough margin, copper levels drop.

Milder gastrointestinal symptoms like nausea and a metallic taste are common complaints with high-dose zinc and are the most frequent reason people stop taking the supplement. If you experience persistent stomach discomfort, ask your eye doctor about formulations using the lower 25 mg zinc dose.

Vitamin E and Prostate Cancer

The AREDS 2 formula contains 400 IU of vitamin E, and this dose has raised concerns in a different context. The SELECT trial, a large cancer prevention study, found that men taking 400 IU of vitamin E daily had a statistically significant increase in prostate cancer risk. The hazard ratio was 1.17, translating to about 1.6 additional cases per 1,000 men per year of supplementation.⁸

The SELECT trial studied healthy men taking vitamin E alone, not in combination with the other AREDS ingredients, so it is not clear whether the same risk applies when vitamin E is part of a multi-nutrient formulation. Still, the finding is hard to ignore. The absolute risk increase is small, but the AREDS 2 supplement is meant to be taken for years, and that duration matters. Men considering AREDS 2 should weigh this potential risk against the benefit of slowing AMD progression, ideally in conversation with both their eye doctor and their primary care physician.

Drug Interactions to Watch For

One interaction that flies under the radar involves warfarin, the blood thinner. Vitamin E has mild anticoagulant properties, and high-dose zinc can affect how warfarin is metabolized. A case report documented a patient on warfarin who experienced a clinically significant bleeding event after starting AREDS formula supplements, with the interaction going unrecognized because the patient’s anticoagulation clinic had not been informed about the new supplement.⁹

If you take warfarin or another blood thinner, tell every provider involved in your care before starting AREDS 2. Your INR levels may need more frequent monitoring after you begin the supplement. The same principle applies to any prescription medication you take regularly: bring the bottle to your pharmacist or doctor and ask about interactions. People tend to treat eye vitamins as harmless over-the-counter products, but the doses in AREDS 2 are pharmacological, not nutritional.

Does Your Genetics Change the Answer?

A provocative line of research has suggested that certain genetic profiles might make AREDS supplements not just less helpful but potentially harmful. Two genes involved in AMD risk, CFH and ARMS2, have been studied for their interaction with the AREDS formula. One analysis found that people carrying two copies of the high-risk CFH variant and no ARMS2 risk copies actually progressed faster to advanced AMD when taking the AREDS formula compared with placebo.¹⁰ Another study from the same data reached a similar conclusion, arguing that individual treatment response is largely determined by genetics and that prescribing should be based on genotype.¹¹

However, an independent re-analysis of the same AREDS data found errors in the datasets used to support these claims and was unable to replicate the genotype-treatment interactions after properly adjusting for the large number of comparisons being made. The re-analysis also tested one of the genotype claims on an independent dataset and found no supporting evidence. The authors concluded that even if such interactions existed, the data did not support the idea that supplementation leads to a large increase in AMD risk for any genotype group.¹²

The current consensus among retina specialists is that genetic testing should not guide the decision to take or avoid AREDS 2 supplements. The original findings of genotype-dependent harm were striking but have not held up under independent scrutiny. That said, this area of research is not dead, and future studies with larger cohorts could reopen the question. For now, the recommendation is the same regardless of your genetic background: if you have intermediate or advanced AMD, AREDS 2 supplementation is a reasonable choice.

Not All AREDS 2 Products Are the Same

Because dietary supplements in the United States are regulated under the 1994 Dietary Supplement Health and Education Act rather than the stricter framework applied to prescription drugs, there is no requirement that a product labeled “AREDS 2” actually match the formula tested in the clinical trial. A study analyzing 120 commercially available products found that nearly a third did not adhere to the AREDS 2 formula. About 14 percent were missing at least one ingredient entirely. Others contained less or more of a given ingredient than the tested formula calls for. Some included extra ingredients not part of the studied formula at all. Ironically, the non-compliant products were on average 26 percent more expensive than the ones that matched the actual AREDS 2 recipe.¹³

If you are going to take AREDS 2, it is worth checking the supplement facts panel against the actual formula: 500 mg vitamin C, 400 IU vitamin E, 10 mg lutein, 2 mg zeaxanthin, 80 mg zinc (or 25 mg in lower-dose versions), and 2 mg copper. A higher price does not signal better adherence to the formula. Some of the most expensive brands on the market are the ones padding their products with extra ingredients that were never tested in the trial or, worse, leaving out ingredients that were.

What AREDS 2 Will Not Do for You

One hope that did not pan out was that the antioxidant and carotenoid ingredients in AREDS 2 might protect cognitive function. An ancillary study within the AREDS 2 trial tracked participants’ cognitive scores over time using validated telephone-based assessments. There was no meaningful difference in the rate of cognitive decline between those who received lutein and zeaxanthin and those who did not. The yearly change in composite cognitive scores was virtually identical between groups.¹⁴ Omega-3 fatty acids similarly showed no cognitive benefit. So while the marketing of some eye vitamins hints at brain-health advantages, the trial data do not support that claim.

AREDS 2 also does not prevent AMD from developing in the first place. Every participant in the trial already had at least intermediate disease. There is no evidence that taking AREDS 2 as a preventive measure in people with healthy eyes does anything useful, and doing so would expose you to the side effects described above with no expected payoff.

The Economic Case

For people who do have AMD, the financial picture depends on disease stage. A UK-based economic model found that AREDS supplementation in patients with the most advanced single-eye disease was actually cost-saving overall, because slowing progression meant fewer expensive anti-VEGF injections. In that group, treated patients needed an average of about eight fewer injections over their lifetime compared with untreated patients. For patients with intermediate AMD, the supplement added a small cost without producing a dramatic gain in quality-adjusted life years, though it still reduced the number of future injections by about three.¹⁵ The practical takeaway is that the further along your AMD is, the stronger the case for supplementation becomes, both medically and financially.

At typical retail prices of around 50 cents to a dollar per day, the supplement itself is not expensive. But over years of daily use, those costs add up, and the benefit is probabilistic rather than guaranteed. AREDS 2 shifts the odds modestly in your favor. For someone whose central vision is at stake, that shift is usually worth the cost and the tolerable side effects. For someone without meaningful AMD risk, the math does not work out.